Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAN-TU-001 Gantenerumab OLE
NCT06424236Phase 3Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2020
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of gantenerumab in Dominantly Inherited Alzheimer's Disease (DIAD), sponsored by Washington University School of Medicine. Started Jun 2020; status: terminated.
02
Drugs
gantenerumab
03
Conditions
Dominantly Inherited Alzheimer's Disease (DIAD)
Beyond the preview
Go deeper on NCT06424236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06424236.